Allograft Dysfunction in Heart Transplant
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03102125 |
Recruitment Status :
Recruiting
First Posted : April 5, 2017
Last Update Posted : November 4, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Heart Transplant Failure and Rejection | Drug: Regadenoson | Phase 4 |
Adult heart-transplant patients, excluding those with a GFR less than 30 mL/min/1.73m2, contraindications to MRI and allergies to either regadenoson or gadolinium contrast, will be enrolled over 60 months. Patients will be recruited from UCSD. The investigators will specifically enroll all eligible heart-transplant patients.
Brief protocol:
Cardiac MRI is performed. Cine images in standard views are obtained. T1 and T2 mapping sequences are performed on short axis images pre- and post-gadolinium contrast. For stress imaging, intravenous regadenoson is given as a 0.4 mg bolus followed by a 5 mL saline flush. After 30 seconds, short-axis images are acquired for 30 consecutive heartbeats with administration of gadolinium. Rest imaging is performed 30 minutes after stress imaging. Lastly, late gadolinium enhancement images are obtained in standard views. Images are analyzed offline by a blinded independent reader. Patients will be followed for at least 1 year after enrollment for MACE.
Peripheral blood and endomyocardial biopsies will also be collected, timing as per usual clinical care as well as for-cause, for single cell RNAseq analyses.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 376 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Diagnostic |
Official Title: | Defining Mechanisms for Cardiac Allograft Dysfunction to Improve Allograft Longevity and Survival in Heart-Transplant Patients |
Actual Study Start Date : | October 1, 2019 |
Estimated Primary Completion Date : | April 1, 2024 |
Estimated Study Completion Date : | April 1, 2024 |

Arm | Intervention/treatment |
---|---|
Experimental: Nonspecific allograft dysfunction
Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
|
Drug: Regadenoson
For use in stress myocardial perfusion imaging.
Other Name: Lexiscan |
Experimental: Normal graft function
Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
|
Drug: Regadenoson
For use in stress myocardial perfusion imaging.
Other Name: Lexiscan |
Experimental: Cardiac allograft vasculopathy
Patients with allograft dysfunction from known cardiac allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
|
Drug: Regadenoson
For use in stress myocardial perfusion imaging.
Other Name: Lexiscan |
Experimental: ACR/AMR
Patients with allograft dysfunction from prior episodes of acute cellular or antibody mediated rejection will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
|
Drug: Regadenoson
For use in stress myocardial perfusion imaging.
Other Name: Lexiscan |
- Myocardial Perfusion Reserve [ Time Frame: 60 months ]
- Rest and stress myocardial blood flow [ Time Frame: 60 months ]
- LGE % [ Time Frame: 60 months ]
- LVEF [ Time Frame: 60 months ]
- LV end-diastolic volume index [ Time Frame: 60 months ]
- LV mass index [ Time Frame: 60 months ]
- native T1 and T2 myocardial values [ Time Frame: 60 months ]
- extracellular volumes [ Time Frame: 60 months ]
- myocardial strain rate [ Time Frame: 60 months ]
- Major adverse cardiovascular events [ Time Frame: 60 months ]death, re-transplantation, percutaneous coronary intervention and HF hospitalization
- Percentage of different T-cell subsets by single cell RNAseq [ Time Frame: 60 months ]
- Number of stenotic microvasculopathy by histopathologic review of endomyocardial biopsy samples [ Time Frame: 60 months ]Each endomyocardial biopsy slide will be reviewed for stenotic microvasculopathy as per Hiemann et al 2007, Circulation. 1 stenotic blood vessel per view on X200 zoom is diagnostic of stenotic microvasculopathy.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age greater than or equal to 18 years old.
- At least three months status post heart transplantation.
Exclusion Criteria:
- Biopsy proven acute rejection episode in the past 3 months.
- Patients with symptoms or signs of acute myocardial ischemia or recent acute coronary syndrome in the past 3 months.
- Uncontrolled obstructive ventilatory disease including asthma and COPD.
- History of generalized tonic-clonic seizures.
- Second or third degree AV nodal block.
- Sinus node dysfunction.
- Contraindications to MRI including cardiovascular implantable electronic devices.
- Renal dysfunction with an estimated GFR less than 30 mL/min/1.73m2.
- Prior adverse reaction to either regadenoson or gadolinium contrast. Prior adverse reaction to adenosine or dipyridamole will be assessed on a case-by-case basis.
- Systolic blood pressure greater than 180 or less than 85 mmHg.
- Diastolic blood pressure greater than 120 or less than 40 mmHg.
- Resting heart rate greater than 120 or less than 45 beats per minute. - Severe claustrophobia.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03102125
Contact: Paul Kim, MD | 8582460638 | pjk017@ucsd.edu |
United States, California | |
UC San Diego | Recruiting |
La Jolla, California, United States, 92037 | |
Contact: Paul Kim, MD 858-246-0638 pjk017@ucsd.edu |
Principal Investigator: | Paul Kim, MD | UC San Diego |
Responsible Party: | Paul Kim, Assistant Professor, University of California, San Diego |
ClinicalTrials.gov Identifier: | NCT03102125 |
Other Study ID Numbers: |
160808 |
First Posted: | April 5, 2017 Key Record Dates |
Last Update Posted: | November 4, 2021 |
Last Verified: | November 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
heart transplant acute graft rejection chronic graft rejection |
Regadenoson Adenosine A2 Receptor Agonists Purinergic P1 Receptor Agonists Purinergic Agonists |
Purinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |